Leap Therapeutics Inc (LPTX) concluded trading on Wednesday at a closing price of $0.45, with 104.16 million shares of worth about $46.87 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -83.27% during that period and on March 26, 2025 the price saw a gain of about 16.88%. Currently the company’s common shares owned by public are about 38.26M shares, out of which, 28.57M shares are available for trading.
Stock saw a price change of 9.28% in past 5 days and over the past one month there was a price change of -6.11%. Year-to-date (YTD), LPTX shares are showing a performance of -84.23% which decreased to -82.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.39 but also hit the highest price of $4.79 during that period. The average intraday trading volume for Leap Therapeutics Inc shares is 756.73K. The stock is currently trading 7.81% above its 20-day simple moving average (SMA20), while that difference is down -46.16% for SMA50 and it goes to -79.50% lower than SMA200.
Leap Therapeutics Inc (NASDAQ: LPTX) currently have 38.26M outstanding shares and institutions hold larger chunk of about 30.21% of that.
The stock has a current market capitalization of $17.38M and its 3Y-monthly beta is at 0.09. It has posted earnings per share of -$1.93 in the same period. It has Quick Ratio of 3.97 while making debt-to-equity ratio of 0.01. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for LPTX, volatility over the week remained 16.72% while standing at 9.26% over the month.
Stock’s fiscal year EPS is expected to rise by 46.96% while it is estimated to increase by 31.25% in next year. EPS is likely to shrink at an annualized rate of 24.79% for next 5-years, compared to annual growth of 28.36% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Robert W. Baird on January 29, 2025 offering a Neutral rating for the stock and assigned a target price range of between $9 and $1.25 to it. On June 28, 2024, Rodman & Renshaw Initiated their recommendations, while on October 04, 2021, Mizuho Initiated their ratings for the stock with a price target of $6. Stock get an Outperform rating from Robert W. Baird on June 04, 2021.
